PARIS, May 15 /PRNewswire-FirstCall/ -- Sanofi-aventis announced that
the U.S. Court of Appeals for the Federal Circuit has affirmed the February
8, 2007 decision by the U.S. District Court for the Central District of
California in the sanofi-aventis Lovenox(R) patent infringement suit
against Amphastar and Teva.
As a result of the Court of Appeals' ruling, the U.S. Lovenox(R) patent
is deemed to be unenforceable.
Sanofi-aventis is considering all its legal options.
While several generic manufacturers have requested marketing approval
from the FDA for their products alleged to be generic versions of
Lovenox(R), sanofi-aventis has not learned of any FDA approval of these
requests.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as defined in
the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts.
These statements include financial projections and estimates and their
underlying assumptions, statements regarding plans, objectives, intentions
and expectations with respect to future events, operations, products and
services, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans" and similar expressions.
Although sanofi-aventis' management believes that the expectations
reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of sanofi-aventis, that could cause actual
results and developments to differ materially from those expressed in, or
implied or projected by, the forward- looking information and statements.
These risks and uncertainties include those discussed or identified in the
public filings with the SEC and the AMF made by sanofi-aventis, including
those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F
for the year ended December 31, 2007. Other than as required by applicable
law, sanofi-aventis does not undertake any obligation to update or revise
any forward-looking information or statements.
CONTACT: Jean-Marc Podvin
sanofi-aventis
+331-53-77-4223
jeanmarc.podvin@sanofi-aventis.com
SOURCE sanofi-aventis
 back to top
Related links:
http://www.sanofi-aventis.us
http://www.sanofi-aventis.com
http://www.prnewswire.com/comp/232375.html /
CONTACT:
Jean-Marc Podvin, Vice President, Media
Relations, sanofi- aventis, +331-53-77-4223, Charles F. Rouse
III, sanofi-aventis, +1-908-243- 6050
|
